Use and safety of denosumab in cancer patients (Q38851098)

7 September 2017

Use and safety of denosumab in cancer patients (English)

1 reference

7 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28382583%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Carla Bastida

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28382583%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Alba Manzaneque

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28382583%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Mireia Mensa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28382583%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Natàlia Creus-Baró

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28382583%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

5 April 2017

1 reference

International Journal of Clinical Pharmacy

7 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28382583%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28382583%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

522-526

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28382583%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28382583%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11096-017-0455-1

4 June 2020

exact match

0 references

cites work

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

1 reference

https://api.crossref.org/works/10.1007%2FS11096-017-0455-1

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-017-0455-1

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-017-0455-1

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-017-0455-1

Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-017-0455-1

Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-017-0455-1

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-017-0455-1

Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-017-0455-1